Comment on: ‘Treatment of psoriasis with ustekinumab in a patient with HIV‐related Kaposi sarcoma’

Abstract

We read with great interest the recent article by Wang et al.¹ reporting on a psoriatic patient co‐affected by HIV‐related Kaposi's sarcoma (KS), whose poorly controlled psoriasis was successfully treated with ustekinumab, a fully monoclonal antibody that targets the common p40 subunit shared by interleukins (IL)‐12 and IL‐23. Interestingly, despite the evidences supporting the role of IL‐12 in inhibiting tumorigenesis,² the authors reported no KS progression after a 16‐month follow‐up.

This article is protected by copyright. All rights reserved.

http://bit.ly/2TltEjC